Altavilla R, et al. - By evaluating data of stroke patients from the prospective RAF and RAF-NOACs studies, researchers compared the clinical profiles of patients receiving and not receiving bridging therapy with low-molecular-weight heparin, overall group outcomes, and outcomes according to the type of anticoagulant prescribed. Of 1,810 subjects who started oral anticoagulant therapy, 371 had bridging therapy. Findings revealed that bridging therapy use was inversely associated with older age and leukoaraiosis presence. According to this observational study, patients getting low-molecular-weight heparin have a higher risk of early ischemic recurrence and hemorrhagic transformation vs nonbridged patients.